The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study

R Provenzano, A Besarab, I C Macdougall, D H Ellison, A P Maxwell, W Sulowicz, M Klinger, B Rutkowski, R Correa-Rotter, F C Dougherty, BA 16528 Study Investigators

Research output: Contribution to journalArticlepeer-review

57 Citations (Scopus)

Abstract

This study was designed to assess the potential of the continuous erythropoietin receptor activator (C.E.R.A.) to correct anemia at extended administration intervals in erythropoiesis-stimulating agent-naīve patients with chronic kidney disease (CKD) not on dialysis and to determine its optimal starting dose.
Original languageEnglish
Pages (from-to)306-17
Number of pages12
JournalClinical nephrology
Volume67
Issue number5
Publication statusPublished - May 2007

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Analysis of Variance
  • Anemia
  • Area Under Curve
  • Biological Markers
  • Dose-Response Relationship, Drug
  • Erythropoiesis
  • Erythropoietin
  • Female
  • Ferritins
  • Follow-Up Studies
  • Hemoglobins
  • Humans
  • Kidney Failure, Chronic
  • Male
  • Middle Aged
  • Polyethylene Glycols
  • Recombinant Proteins
  • Regression Analysis
  • Renal Dialysis
  • Time Factors
  • Treatment Outcome

Fingerprint Dive into the research topics of 'The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study'. Together they form a unique fingerprint.

Cite this